Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Measles, Mumps, and Rubella Virus Vaccine Live
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Measles, Mumps, and Rubella Virus Vaccine Live is a trivalent live-attenuated vaccine designed to provide active immunity against measles (rubeola), mumps, and rubella (German measles). This specific drug entry refers to the vaccine as utilized in clinical development programs by Sanofi Pasteur, particularly in studies evaluating the safety and immunogenicity of concomitant administration with other pediatric vaccines, such as the quadrivalent meningococcal conjugate vaccine (MenACYW/MenQuadfi). The vaccine contains weakened strains of the measles, mumps, and rubella viruses that replicate at a low level to stimulate a robust immune response, including the production of neutralizing antibodies and memory T cells, without causing the diseases in healthy individuals. In the context of Sanofi's meningococcal trials, the MMR vaccine is administered to infants and toddlers to ensure that co-vaccination does not interfere with the protective immune response of either the routine or the investigational vaccine.
- Brand names
- TrimovaxPriorixM-M-R II
- Other names
- MMR vaccineMeasles, Mumps, and Rubella Virus Vaccine Live-Sanofi PasteurLive attenuated measles, mumps and rubella vaccine
Beyond the preview
Go deeper on Measles, Mumps, and Rubella Virus Vaccine Live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Measles, Mumps, and Rubella Virus Vaccine Live.